Uptake of risk-reducing salpingo-oophorectomy among female BRCA mutation carriers: experience at the National Cancer Center of Korea

Journal of Cancer Research and Clinical Oncology

Volumn 142, Issue 1, 2016, Pages 333-340

  Kim, Se Ik ^a,b   Lim, Myong Cheol ^a   Lee, Dong Ock ^a   Kong, Sun Young ^a   Seo, Sang Soo ^a   Kang, Sokbom ^a   Lee, Eun Sook ^a   Park, Sang Yoon ^a  

^a National Cancer Center   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

Author keywords

BRCA1; BRCA2; Breast cancer; Ovarian cancer; Risk reducing surgery; Salpingo oophorectomy

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CA 125 ANTIGEN; BRCA1 PROTEIN, HUMAN; BRCA2 PROTEIN, HUMAN;

ADULT; AMENORRHEA; ARTICLE; BREAST CANCER; CLINICAL FEATURE; COHORT ANALYSIS; DEMOGRAPHY; FAMILY HISTORY; FEMALE; FRAMESHIFT MUTATION; GENETIC COUNSELING; GENETIC SCREENING; HUMAN; KOREA; LAPAROSCOPIC SURGERY; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MIDDLE AGED; NONSENSE MUTATION; OVARY CANCER; PERITONEUM CANCER; PREVALENCE; PRIORITY JOURNAL; RISK REDUCING SALPINGOOOPHORECTOMY; RISK REDUCTION; SALPINGOOOPHORECTOMY; BREAST NEOPLASMS; CANCER STAGING; FOLLOW UP; GENETIC PREDISPOSITION; GENETICS; HETEROZYGOTE; MUTATION; OVARIAN NEOPLASMS; OVARIECTOMY; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR; SALPINGECTOMY; SOUTH KOREA;

ADULT; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HUMANS; MIDDLE AGED; MUTATION; NEOPLASM STAGING; OVARIAN NEOPLASMS; OVARIECTOMY; PROGNOSIS; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; RISK FACTORS; RISK REDUCTION BEHAVIOR; SALPINGECTOMY;

EID: 84953639176     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-015-2051-x     Document Type: Article

References (44)

1. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL et al (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72:1117–1130
2. Armstrong K, Schwartz JS, Randall T, Rubin SC, Weber B (2004) Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: a decision analysis. J Clin Oncol 22:1045–1054
3. Beattie MS, Crawford B, Lin F, Vittinghoff E, Ziegler J (2009) Uptake, time course, and predictors of risk-reducing surgeries in BRCA carriers. Genet Test Mol Biomark 13:51–56
4. Borzekowski DL, Guan Y, Smith KC, Erby LH, Roter DL (2014) The Angelina effect: immediate reach, grasp, and impact of going public. Genet Med 16:516–521
5. Bradbury AR, Ibe CN, Dignam JJ, Cummings SA, Verp M, White MA et al (2008) Uptake and timing of bilateral prophylactic salpingo-oophorectomy among BRCA1 and BRCA2 mutation carriers. Genet Med 10:161–166
6. Chen S, Parmigiani G (2007) Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 25:1329–1333
7. Choi DH, Lee MH, Bale AE, Carter D, Haffty BG (2004) Incidence of BRCA1 and BRCA2 mutations in young Korean breast cancer patients. J Clin Oncol 22:1638–1645
8. Daly MB, Pilarski R, Axilbund JE, Buys SS, Crawford B, Friedman S et al (2014) Genetic/familial high-risk assessment: breast and ovarian, version 1.2014. J Natl Compr Cancer Netw 12:1326–1338
9. Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C et al (2010) Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 304:967–975
10. Evans DG, Barwell J, Eccles DM, Collins A, Izatt L, Jacobs C et al (2014) The Angelina Jolie effect: how high celebrity profile can have a major impact on provision of cancer related services. Breast Cancer Res 16:442
11. Fang CY, Cherry C, Devarajan K, Li T, Malick J, Daly MB (2009) A prospective study of quality of life among women undergoing risk-reducing salpingo-oophorectomy versus gynecologic screening for ovarian cancer. Gynecol Oncol 112:594–600
12. Finch A, Shaw P, Rosen B, Murphy J, Narod SA, Colgan TJ (2006) Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol Oncol 100:58–64
13. Finch A, Metcalfe KA, Chiang JK, Elit L, McLaughlin J, Springate C et al (2011) The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation. Gynecol Oncol 121:163–168
14. Finch AP, Lubinski J, Møller P, Singer CF, Karlan B, Senter L et al (2014) Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol 32:1547–1553
15. Grann VR, Jacobson JS, Thomason D, Hershman D, Heitjan DF, Neugut AI (2002) Effect of prevention strategies on survival and quality-adjusted survival of women with BRCA1/2 mutations: an updated decision analysis. J Clin Oncol 20:2520–2529
16. Greene MH, Piedmonte M, Alberts D, Gail M, Hensley M, Miner Z et al (2008) A prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: design and baseline characteristics: a Gynecologic Oncology Group study. Cancer Epidemiol Biomark Prev 17:594–604
17. Hirst JE, Gard GB, McIllroy K, Nevell D, Field M (2009) High rates of occult fallopian tube cancer diagnosed at prophylactic bilateral salpingo-oophorectomy. Int J Gynecol Cancer 19:826–829
18. Jung KW, Won YJ, Oh CM, Kong HJ, Cho H, Lee DH, Lee KH (2015) Prediction of cancer incidence and mortality in Korea, 2015. Cancer Res Treat 47:142–148
19. Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA et al (2002) Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346:1609–1615
20. Kim H, Cho DY, Choi DH, Choi SY, Shin I, Park W et al (2012) Characteristics and spectrum of BRCA1 and BRCA2 mutations in 3,922 Korean patients with breast and ovarian cancer. Breast Cancer Res Treat 134:1315–1326
21. Kim D, Kang E, Hwang E, Sun Y, Hwang Y, Yom CK et al (2013) Factors affecting the decision to undergo risk-reducing salpingo-oophorectomy among women with BRCA gene mutation. Fam Cancer 12:621–628
22. Laki F, Kirova YM, This P, Plancher C, Asselain B, Sastre X et al (2007) Prophylactic salpingo-oophorectomy in a series of 89 women carrying a BRCA1 or a BRCA2 mutation. Cancer 109:1784–1790
23. Levy-Lahad E, Friedman E (2007) Cancer risks among BRCA1 and BRCA2 mutation carriers. Br J Cancer 96:11–15
24. Lim MC, Kang S, Seo SS, Kong SY, Lee BY, Lee SK et al (2009) BRCA1 and BRCA2 germline mutations in Korean ovarian cancer patients. J Cancer Res Clin Oncol 135:1593–1599
25. Lim MC, Moon EK, Shin A, Jung KW, Won YJ, Seo SS et al (2013) Incidence of cervical, endometrial, and ovarian cancer in Korea, 1999-2010. J Gynecol Oncol 24:298–302
26. M.D. Anderson Cancer Center (2013) Prophylactic salpingectomy with delayed oophorectomy. https://clinicaltrials.gov/ct2/show/NCT01907789/. Accessed 30 June 2015
27. Madalinska JB, van Beurden M, Bleiker EM, Valdimarsdottir HB, Hollenstein J, Massuger LF et al (2006) The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy. J Clin Oncol 24:3576–3582
28. Madalinska JB, van Beurden M, Bleiker EM, Valdimarsdottir HB, Lubsen-Brandsma L, Massuger LF et al (2007) Predictors of prophylactic bilateral salpingo-oophorectomy compared with gynecologic screening use in BRCA1/2 mutation carriers. J Clin Oncol 25:301–307
29. Mai PL, Loud JT, Greene MH (2014) A major step forward for BRCA1/2-related cancer risk management. J Clin Oncol 32:1531–1533
30. Meijers-Heijboer EJ, Verhoog LC, Brekelmans CT, Seynaeve C, Tilanus-Linthorst MM, Wagner A et al (2000) Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation. Lancet 355:2015–2020
31. Meijers-Heijboer H, van Geel B, van Putten WL, Henzen-Logmans SC, Seynaeve C, Menke-Pluymers MB et al (2001) Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 345:159–164
32. Metcalfe KA, Birenbaum-Carmeli D, Lubinski J, Gronwald J, Lynch H, Moller P et al (2008a) International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. Int J Cancer 122:2017–2022
33. Metcalfe KA, Foulkes WD, Kim-Sing C, Ainsworth P, Rosen B, Armel S et al (2008b) Family history as a predictor of uptake of cancer preventive procedures by women with a BRCA1 or BRCA2 mutation. Clin Genet 73:474–479
34. NICE guidelines (2013) Familial breast cancer: classification and care of people at risk of familial breast cancer and management of breast cancer and related risks in people with a family history of breast cancer. http://www.nice.org.uk/guidance/cg164. Accessed 30 June 2015
35. Powell CB, Kenley E, Chen LM, Crawford B, McLennan J, Zaloudek C et al (2005) Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. J Clin Oncol 23:127–132
36. Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van’t Veer L, Garber JE et al (2002) Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346:1616–1622
37. Rebbeck TR, Friebel T, Wagner T, Lynch HT, Garber JE, Daly MB et al (2005) Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 23:7804–7810
38. Schmeler KM, Sun CC, Bodurka DC, White KG, Soliman PT, Uyei AR et al (2006) Prophylactic bilateral salpingo-oophorectomy compared with surveillance in women with BRCA mutations. Obstet Gynecol 108:515–520
39. Schwartz MD, Kaufman E, Peshkin BN, Isaacs C, Hughes C, DeMarco T et al (2003) Bilateral prophylactic oophorectomy and ovarian cancer screening following BRCA1/BRCA2 mutation testing. J Clin Oncol 21:4034–4041
40. Seo JH, Cho DY, Ahn SH, Yoon KS, Kang CS, Cho HM et al (2004) BRCA1 and BRCA2 germline mutations in Korean patients with sporadic breast cancer. Hum Mutat 24:350
41. Seong MW, Cho S, Noh DY, Han W, Kim SW, Park CM et al (2009) Comprehensive mutational analysis of BRCA1/BRCA2 for Korean breast cancer patients: evidence of a founder mutation. Clin Genet 76:152–160
42. Stuckey A, Dizon D, Scalia Wilbur J, Kent J, Tejada-Berges T, Gass J, Legare R (2010) Clinical characteristics and choices regarding risk-reducing surgery in BRCA mutation carriers. Gynecol Obstet Invest 69:270–273
43. Uyei A, Peterson SK, Erlichman J, Broglio K, Yekell S, Schmeler K et al (2006) Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study. Cancer 107:2745–2751
44. WHO (2015) World Health Statistics 2015. http://who.int/gho/publications/world_health_statistics/2015/en/. Accessed 30 June 2015